Effect of Adding L-Carnitine to Clomiphene Resistant PCOs Women on the Ovulation and the Pregnancy Rate

Abd-Elfattah, Ahmed Taha; El-Omda, Fahd Abd El-Aal; Hashish, Mahmoud; Megahed, Hossam Ibrahim

doi:10.21608/ejhm.2019.43079

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, the number of follicles larger than 17 mm, the concentration of estradiol and the thickness of the endometrium were significantly higher in the L-carnitine group [ 9 ]. In a similar randomized clinical trial with a smaller sample size, Abdelfattah et al, confirmed that adding L-carnitine to clomiphene citrate in the follicular phase and continuing administration into the luteal phase in clomiphene-resistant patients can improve ovulation quality and the rates of chemical and clinical pregnancy [ 18 ]. In contrast, another RCT showed that the addition of L-carnitine to clomiphene citrate in women with PCOS could improve the number and quality of mature oocytes; however, the pregnancy rate did not change significantly [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

Adding L-carnitine to antagonist ovarian stimulation doesn’t improve the outcomes of IVF/ ICSI cycle in patients with polycystic ovarian syndrome: a double-blind randomized clinical trial

Hafezi,

Arabipoor,

Ghaffari

et al. 2024

J Ovarian Res

View full text Add to dashboard Cite

Objective To investigate the effect of L-carnitine supplementation during the controlled ovarian stimulation (COS) cycle with antagonist protocol in patients with polycystic ovary syndrome (PCOS) diagnosis undergoing IVF/ICSI treatment. Methods and materials This was a double-blind clinical trial study including 110 patients with PCOS attended to Royan Institute between March 2020 and February 2023. At the beginning of the COS cycle, the eligible patients were allocated into two groups randomly according to the coding list of the drugs prepared by the statistical consultant. In the experimental group, patients received 3 tablets daily (L-carnitine 1000 mg) from the second day of menstruation of the previous cycle until the puncture day in the cases of freeze-all embryos (6 weeks) or until the day of the pregnancy test (8 weeks) in fresh embryo transfer cycle. In the control group, patients received 3 placebo tablets for the same period of time. Weight assessment and fasting blood sugar and insulin tests, as well as serum lipid profile were also measured at the baseline and ovum pick-up day. The results of the COS cycle as well as the implantation and pregnancy rates were compared between groups. Results Finally, 45 cases in L-carnitine group versus 47 cases in the placebo group were completed study per protocol. Data analysis showed that the two groups were homogeneous in terms of demographic characteristics and baseline laboratory tests and severity of PCOS. There is no statistically significant difference in terms of the oocyte recovery ratio and oocyte maturity rate, and the number and quality of embryos, as well as the rates of the fertilization, chemical and clinical pregnancy between groups. However, the means of weight (P < 0.001) and serum levels of fasting blood sugar (P = 0.021), fasting insulin (P = 0.004), triglyceride (P < 0.001) and cholesterol (P < 0.001), LDL (P < 0.001) have significantly decreased in women after consuming L-carnitine supplementation. Conclusion The oral intake of L-carnitine during COS in PCOS women for 6 weeks had no effect on COS and pregnancy outcomes. However, taking this supplement for 6 weeks has been associated with weight loss and improved lipid profile and serum glucose. Trial registration The study was registered in the Clinicaltrials.gov site on December 17, 2020 (NCT04672720).

show abstract

Section: Discussionmentioning

confidence: 99%

Adding L-carnitine to antagonist ovarian stimulation doesn’t improve the outcomes of IVF/ ICSI cycle in patients with polycystic ovarian syndrome: a double-blind randomized clinical trial

Hafezi,

Arabipoor,

Ghaffari

et al. 2024

J Ovarian Res

View full text Add to dashboard Cite

show abstract

“…"Chronic hyperglycemia in synergy with the other metabolic aberrations in diabetic patients can cause damage to various organ systems, leading to the development of disabling and lifethreatening health complications, most prominent of which are micro vascular (retinopathy, nephropathy, and neuropathy) and macro vascular complications leading to a 2-fold to a 4fold increased risk of cardiovascular diseases. In 2015, the International Diabetic Federation estimated that the prevalence of diabetes was 8.8% from ages 20 to 79 years affecting a population of approximately 440 million people" [2].…”

Section: Introductionmentioning

confidence: 99%

“…The duration and severity of hyperglycemia is the major causative factor in initiating organ damage. Early morphological signs of renal damage include nephromegaly and a modified Doppler, but the degree of damage is best ascertained from proteinuria and Glomerular filtration rate (GFR)" [2][3].…”

Section: Introductionmentioning

confidence: 99%

Significance of Serum Relaxin in Diabetic and Non-Diabetic Patients with Chronic Kidney Disease

Elashmoney

El-Gharbawy

Hodeib

et al. 2022

JAMMR

View full text Add to dashboard Cite

Diabetes mellitus (DM) is a chronic metabolic disorder characterized by persistent hyperglycemia. It may be due to impaired insulin secretion, resistance to peripheral actions of insulin, or both. The aim of the work is to evaluate significance of serum relaxin in diabetic and non-diabetic patients with chronic kidney disease. 60 subjects aged from (18years to 60 years) in internal medicine department at Tanta University hospital (outpatient –inward). This study was carried out from between March 2020 to March 2021. There was insignificant difference between groups according to age There was an inverse significant correlation between serum relaxin level and HBA1C in group 2 .but not in group 3. There was an inverse significant correlation between serum relaxin level and creatinine in group 2 .and in group 3. the best cut of level of relaxin hormone in discriminating normal individuals fron CKD patients was 150 ng/dl with an area under the curve(AUC) of 0,988 yeilding sensitivity of 93%, specifity of 95% , positive predictive value (PPV) 97%, negative predictive value(NPV) 86% and accuracy of 93%. Serum RLX levels are significantly lower in patients with CKD than healthy subjects. Furthermore, when compared to non-diabetic patients, they are much lower in diabetic patients. This research suggests that RLX could be a useful therapeutic option for diabetic nephropathy patients with developed fibrosis. RLX has a high safety profile, with potentially fewer adverse effects than conventional treatments because it is a naturally occurring physiological hormone. However, further effort is required.

show abstract

Acetyl-l-Carnitine Ameliorates Metabolic and Endocrine Alterations in Women with PCOS: A Double-Blind Randomized Clinical Trial

et al. 2021

View full text Add to dashboard Cite

Effect of Adding L-Carnitine to Clomiphene Resistant PCOs Women on the Ovulation and the Pregnancy Rate

Cited by 4 publications

References 0 publications

Adding L-carnitine to antagonist ovarian stimulation doesn’t improve the outcomes of IVF/ ICSI cycle in patients with polycystic ovarian syndrome: a double-blind randomized clinical trial

Adding L-carnitine to antagonist ovarian stimulation doesn’t improve the outcomes of IVF/ ICSI cycle in patients with polycystic ovarian syndrome: a double-blind randomized clinical trial

Significance of Serum Relaxin in Diabetic and Non-Diabetic Patients with Chronic Kidney Disease

Acetyl-l-Carnitine Ameliorates Metabolic and Endocrine Alterations in Women with PCOS: A Double-Blind Randomized Clinical Trial

Contact Info

Product

Resources

About